Filing Flows › Lexicon Pharmaceuticals (LXRX) › Q4 2025
Lexicon Pharmaceuticals (LXRX) Q4 2025 earnings results (fourth quarter 2025)
10-K filed Mar 5, 2026
Lexicon Pharmaceuticals (LXRX) reported revenue of $5.5M for the fourth quarter 2025 (Q4 2025), -79% from a year earlier and -61% from the quarter before. Operating margin was -269.1%, net loss $15.5M (282.7% of revenue).
Lexicon Pharmaceuticals, Q4 2025: revenue $5.5M (-79% year over year), operating margin -269.1%, net loss $15.5M, operating cash flow −$17.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.5M | -61% | -79% |
| Operating profit | −$14.8M | — | — |
| Net earnings | −$15.5M | — | — |
| Operating cash flow | −$17.2M | — | — |
What changed
Revenue was $5.5M in Q4 2025, down 79% year over year and down 61% from the previous quarter.
Operating costs exceeded revenue by $14.8M, an operating margin of -269.1%. Total costs fell 66% while revenue fell 79%. The quarter ended with a net loss of $15.5M, wider than the previous quarter's $12.8M loss.
Operating cash flow was −$17.2M. Non-cash charges added back $118K of depreciation and amortization and $2.8M of share-based compensation. Working capital and other items used $4.7M.
Questions
What was Lexicon Pharmaceuticals' revenue in the fourth quarter 2025?
Lexicon Pharmaceuticals (LXRX) reported revenue of $5.5M for the fourth quarter 2025 (Q4 2025), -79% from a year earlier and -61% from the quarter before.
Was Lexicon Pharmaceuticals profitable in the fourth quarter 2025?
Operating loss was $14.8M (-269.1% of revenue) and net loss $15.5M.